🧬 RETATRUTIDE & CARDIOMETABOLIC RESEARCH
TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes.
At 80 weeks, the 12 mg trial group had a reported average 22.6% reduction in body weight.
Researchers also reported changes in several cardiometabolic risk markers, including triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, and hsCRP.
One especially important detail: the trial did not establish superiority for major cardiovascular events; the reported confidence intervals included no difference.
That’s why reading the whole result matters more than grabbing the most exciting number.
Retatrutide remains investigational and is not FDA-approved as of this post. 🧬